The antidiabetic agents, dipeptidyl peptidase IV inhibitors, were found to reduce glucose fluctuations and plasma nitrotyrosine, IL-6, and IL-18 levels (p<0.05) in type 2 diabetic patients after 3 months of treatment [29]. The gene discussed is IL18; the disease is type 2 diabetes mellitus.